Veterinary · Public health, regulation and professional practice · also Veterinary Pharmacy, Prescribing and Dispensing
Writing a lawful prescription and dispensing safely: who may prescribe, extra-label use and the cascade, withdrawal periods and MRLs, drugs prohibited in food animals, pharmacovigilance, controlled drugs and records.
In the exams: EAEVE Day One competences on prescribing, dispensing and reporting adverse reactions; WOAH Day 1 veterinary products; RCVS Day One competences (the cascade)
Veterinary pharmacy is the part of practice where a clinical decision becomes a legal act. Choosing a drug is pharmacology; writing it down so that a pharmacist, a farmer or a nurse can supply and give it safely, choosing a lawful product, telling the owner how long milk, meat and eggs must be kept out of the food chain, keeping the stock secure, recording what went where, and reporting when something goes wrong is pharmacy and medicines law. This manual covers that ground: the legal categories of medicines and who may prescribe them, dosage forms and compounding, the calculations a veterinarian does every day, prescription writing and dispensing, off-label use under the UK and EU cascade and the US Animal Medicinal Drug Use Clarification Act (AMDUCA), withdrawal periods and maximum residue limits, drugs banned in food-producing animals, controlled drugs, pharmacovigilance, storage, disposal and record keeping.
Medicines law is national, and it changes often. The European Union rewrote its rules in Regulation (EU) 2019/6, which has applied since 28 January 2022. Great Britain regulates through the Veterinary Medicines Regulations 2013, amended since, under the Veterinary Medicines Directorate (VMD). The United States splits responsibility between the Food and Drug Administration (drugs), the Department of Agriculture (vaccines and other biologics) and the Environmental Protection Agency (many pesticides, including some topical parasiticides). India regulates through the Drugs and Cosmetics Act 1940 and its 1945 Rules, the Indian Veterinary Council Act 1984 and food-safety regulations under the Food Safety and Standards Authority of India (FSSAI). This manual teaches the principles that these systems share, says plainly where they differ, and names a statute or section only where it is certain. Before acting on any rule, read the current text in your own country.
Examiners treat this as Day One competence: EAEVE, the RCVS and WOAH all expect a new graduate to prescribe and dispense responsibly, apply the cascade or its local equivalent, and report suspected adverse reactions. Calculation questions appear in every licensing paper because dosing errors are among the commonest and most dangerous mistakes in practice.
Any dose or withdrawal figure in this manual illustrates a method. It is not a recommendation for a particular animal. Every real dose is followed by the reminder to confirm it against the product label and your national formulary, because authorised doses, species and withdrawal periods differ between products and countries.
A veterinary medicinal product is any substance or combination presented as treating or preventing disease in animals, or given to animals to restore, correct or modify physiological functions or to make a diagnosis. Almost every country requires such a product to hold a marketing authorisation (called registration in some countries and approval in the United States) before it may be sold. The authorisation is granted after the regulator has assessed three things: quality (the product is what it says it is, made consistently), safety (to the target animal, to the person giving it, to the consumer of food from treated animals and to the environment) and efficacy (it works for the claims on the label). For food-producing species the consumer-safety assessment includes setting a maximum residue limit and a withdrawal period.
The authorisation fixes the conditions of use: species, indications, dose, route, duration, contraindications, withdrawal period and storage. These are written in the summary of product characteristics (SPC) in the UK and EU, or on the approved label and package insert in the United States. Using a product as the SPC or label says is on-label use. Anything else, such as a different species, dose, route, duration or indication, is off-label or extra-label use, which most countries allow only under defined conditions.
Different bodies regulate in different countries. In Great Britain it is the Veterinary Medicines Directorate under the Veterinary Medicines Regulations 2013; in the EU, national competent authorities and the European Medicines Agency under Regulation (EU) 2019/6; in the United States the FDA Center for Veterinary Medicine for drugs, the USDA Center for Veterinary Biologics for vaccines, and the EPA for many pesticides; in Australia the Australian Pesticides and Veterinary Medicines Authority (APVMA); in New Zealand the Agricultural Compounds and Veterinary Medicines regime; in Canada Health Canada's Veterinary Drugs Directorate; and in India the Central Drugs Standard Control Organisation, with state drug controllers licensing sale.
Each country sorts medicines into legal categories that decide who may prescribe and who may supply. Students must know the categories in their own jurisdiction and recognise the others.
Great Britain uses four categories. POM-V (prescription-only medicine, veterinarian) may be prescribed only by a veterinary surgeon, after clinical assessment of an animal under that vet's care, and supplied by a vet or a pharmacist against a written prescription. POM-VPS (prescription-only medicine, veterinarian, pharmacist, suitably qualified person) may be prescribed and supplied by a vet, a pharmacist or a registered suitably qualified person (SQP); most farm anthelmintics fall here. NFA-VPS (non-food animal, veterinarian, pharmacist, SQP) covers medicines for companion animals that need advice at supply but no prescription. AVM-GSL (authorised veterinary medicine, general sales list) may be sold by any retailer.
The EU, under Regulation 2019/6, defines which products are subject to veterinary prescription. The list includes all antimicrobials, all medicines for food-producing animals with some exceptions, psychotropics, and products with special precautions, and member states may add national categories.
The United States has two federal classes for animal drugs: prescription (Rx), whose label carries the legend that federal law restricts the drug to use by or on the order of a licensed veterinarian, and over-the-counter (OTC). A third route, the Veterinary Feed Directive (VFD), covers medically important antimicrobials in animal feed. In 2023 the FDA completed moving the remaining OTC medically important antimicrobials to prescription status.
India classifies drugs in the schedules of the Drugs and Cosmetics Rules 1945. Schedule H drugs, which include most antibiotics, may be sold by retail only on the prescription of a registered medical practitioner; Schedule H1 drugs, which include several newer antibiotics, also require the seller to keep a separate register; Schedule X drugs, which include certain psychotropics, carry the strictest controls. A registered veterinarian prescribes for animals within this framework. Labels of veterinary products must state that they are not for human use.
The right to prescribe follows from the right to practise. In India, Section 30 of the Indian Veterinary Council Act 1984 provides that only a person whose name is on the Indian Veterinary Practitioners Register (or a State register) may practise veterinary medicine, hold a veterinary post in government or public institutions, sign or authenticate a veterinary certificate, or give evidence in court as an expert in veterinary medicine. Its proviso lets persons with a diploma or certificate in livestock work, such as stockmen and veterinary field assistants, render minor veterinary services, for example first aid, vaccination, castration and wound dressing, under the supervision of a registered practitioner, where the State Government permits. A paravet is therefore not a prescriber of antibiotics or other prescription drugs in his own right.
In the United States the key concept is the veterinarian-client-patient relationship (VCPR). The federal definition used for extra-label use and for the VFD (21 CFR 530.3(i)) has three elements: the veterinarian has assumed responsibility for clinical judgements about the animal's health and the client has agreed to follow instructions; the veterinarian has sufficient knowledge of the animal to make at least a general or preliminary diagnosis, because the vet has recently seen the animal or made timely visits to the premises where it is kept; and the veterinarian is readily available for follow-up in case of adverse reactions or failure of therapy. States define their own VCPR in their practice acts, often adding medical records and emergency-cover duties, and some now allow a VCPR to be formed by telemedicine. The FDA's position is that a federal VCPR cannot be established by telemedicine alone.
In the United Kingdom a vet may prescribe a POM-V only for an animal under his or her care, a phrase the RCVS defines: the vet has been given responsibility for the animal's health by the owner, and has assessed it recently or often enough to have personal knowledge of its condition. RCVS guidance revised in 2023 allows some POM-V prescribing after a remote assessment, but for certain classes, notably antimicrobials, a physical examination is expected except in exceptional circumstances. The EU requires a clinical examination or other proper assessment before any veterinary prescription.
A dosage form is the physical form in which a drug is given. The choice affects absorption, duration, palatability, safety for the handler and, in food animals, the residue profile.
Oral solid forms include tablets, capsules, chewable tablets, boluses for ruminants and pastes for horses. A scored tablet may be split along its score. Film-coated tablets can usually be split if the label allows; enteric-coated and modified-release tablets should not be split or crushed, because the coating protects the drug from stomach acid or controls its release. Capsules hide taste but are hard to divide. Intraruminal devices release drug slowly in the rumen for weeks. Oral liquids include solutions (drug dissolved), suspensions (fine solid particles dispersed, which must be shaken before each dose) and emulsions. Medicated feed, premixes and water-soluble powders treat groups.
Parenteral forms are given by injection. Aqueous solutions act quickly; suspensions and oily vehicles act as depots and prolong absorption, which also prolongs residues at the injection site. Long-acting injections are convenient but carry longer withdrawal periods. Only products labelled for intravenous use may be given intravenously; suspensions and oily products must never go into a vein. Implants and intravaginal devices release hormones over days.
Local forms include intramammary tubes (lactating-cow and dry-cow formulations differ in vehicle and withdrawal, and must not be swapped), ophthalmic drops and ointments, otic preparations, topical creams and ointments, pour-on, spot-on and spray formulations, plunge dips, and medicated ear tags and collars. Pour-ons and spot-ons are absorbed through skin, so the operator needs protection and treated animals should not be handled or licked until dry.
Compounding, also called extemporaneous preparation, means a pharmacist or veterinarian making a medicine for an individual patient by mixing, diluting or reformulating ingredients, for example turning a tablet into a flavoured suspension for a cat or making a lower-strength preparation for a small exotic species. It is lawful in most countries only as a last resort, when no authorised product meets the clinical need: it is the final step of the UK and EU cascade, and in the United States it is extra-label use subject to AMDUCA and FDA policy. Compounding from bulk active pharmaceutical ingredients rather than from authorised finished products is more tightly restricted, and in the US is governed by FDA guidance that has changed over time.
A compounded product has not been tested for stability, bioavailability or uniformity, so the prescriber carries the responsibility. Good practice is to start from an authorised finished product where possible, use a validated formula from a pharmacy reference, choose a vehicle that does not harm the species, assign a short beyond-use date, label clearly with the strength, and tell the owner that the product is unauthorised.
Some excipients are species-specific hazards. Xylitol, a sweetener in some human oral liquids and chewing gum, causes hypoglycaemia and liver failure in dogs. Benzyl alcohol, a preservative, and propylene glycol, a vehicle, are poorly tolerated by cats. Never compound a product for food-producing animals from a substance that has no maximum residue limit, because there is then no lawful withdrawal period.
Most dosing errors are arithmetic or unit errors, and many are tenfold. Learn the conventions and check every calculation twice, ideally with a second person for high-risk drugs.
Percentage weight in volume (% w/v) is grams of solute per 100 mL of solution. A 1% w/v solution therefore contains 1 g per 100 mL, which is 10 mg/mL; to convert % w/v to mg/mL, multiply by 10. A 2% solution is 20 mg/mL and a 5% solution is 50 mg/mL; 5% glucose contains 50 g per litre. Percentage weight in weight (% w/w) is grams per 100 g, used for ointments and powders. Percentage volume in volume (% v/v) is millilitres per 100 mL, used for liquids mixed in liquids.
Ratio strength expresses weak solutions as 1 part in a number of parts. For a solid in a liquid, 1:1000 means 1 g in 1000 mL, which is 1 mg/mL; 1:10,000 is 0.1 mg/mL. Adrenaline (epinephrine) is supplied in both strengths, and confusing them is a classic tenfold error.
Parts per million (ppm) is milligrams per kilogram, or milligrams per litre for dilute aqueous solutions, which equals grams per tonne of feed. A feed containing 100 g of drug per tonne is at 100 ppm.
Dilution uses the relation C1 × V1 = C2 × V2: the amount of drug does not change when diluent is added. To make 100 mL of a 0.5% solution from a 2% stock, V1 = 0.5 × 100 / 2 = 25 mL of stock, made up to 100 mL with 75 mL of diluent. A common error is to add 100 mL of diluent to the stock, which gives the wrong final volume.
Milliequivalents (mEq) express electrolytes by charge: mEq = mmol × valence. For a monovalent ion such as potassium, 1 mmol is 1 mEq.
The basic dose calculation has three steps. Dose in mg = dose rate (mg/kg) × body weight (kg). Volume in mL = dose in mg ÷ concentration (mg/mL). Number of tablets = dose in mg ÷ tablet strength, rounded to a practical fraction that the tablet allows. For a 25 kg dog given a drug at 10 mg/kg from a 50 mg/mL solution, the dose is 250 mg and the volume 5 mL. Convert pounds to kilograms first (1 kg = 2.2 lb), because a dose rate in mg/kg applied to a weight in pounds overdoses by a factor of 2.2. The total quantity to dispense is the dose × doses per day × days.
A constant-rate infusion (CRI) delivers drug continuously. For a dose rate in micrograms per kilogram per minute, the pump rate in mL/h = dose rate (µg/kg/min) × body weight (kg) × 60 ÷ concentration (µg/mL). For a 20 kg dog at 2 µg/kg/min from a 1 mg/mL (1000 µg/mL) solution the rate is 2.4 mL/h. Alternatively the drug is added to a fluid bag: work out the mg needed per hour, divide by the fluid rate in mL/h to get the mg needed per mL of fluid, and multiply by the bag volume. Remove an equal volume of fluid first if precision matters, and label the bag with the drug, amount and time added.
Drip rate for gravity sets is drops per minute = volume (mL) × drop factor (drops/mL) ÷ time (minutes). Giving sets deliver about 15 or 20 drops/mL (adult sets) and 60 drops/mL (paediatric sets); always read the factor on the set.
Doses for cytotoxic drugs are often given per square metre of body surface area (BSA). BSA (m²) = K × (body weight in grams)^(2/3) ÷ 10,000, with K = 10.1 for dogs and 10.0 for cats.
Group medication in water or feed starts from the total daily dose for the group: number of animals × mean weight × dose rate. Divide by the expected daily water intake (or feed intake) to get the inclusion concentration. Sick animals drink and eat less, so the actual dose taken may fall short; this is a known weakness of mass medication.
A prescription is a written instruction from a prescriber to a person who will supply a medicine, and through that person to the animal's keeper. It must be legible, unambiguous and complete, because the pharmacist cannot examine the animal. The traditional parts are the superscription (the symbol Rx, meaning take), the inscription (the drug name, strength and dosage form), the subscription (the quantity to supply and any instructions to the dispenser) and the signa or transcription (the directions to the client, written on the label).
Legal requirements differ, but most include: the date; the prescriber's name, address, telephone, qualifications and registration number; the client's name and address; identification of the animal or group, including species and, for food animals, the herd, flock or individual identity; the name of the medicine, preferably the generic or active-ingredient name, with strength, dosage form and quantity; the dose, route, frequency and duration; the withdrawal period for food-producing animals; any warnings; the number of times it may be repeated; a statement such as for animal treatment only; and the prescriber's signature. The EU's Regulation 2019/6 lists the minimum elements of a veterinary prescription, which include the withdrawal period even where it is zero, and a statement where the product is prescribed under the cascade. Great Britain's Veterinary Medicines Regulations similarly list required particulars and set a maximum validity; prescriptions for Schedule 2 and 3 controlled drugs in the UK are valid for 28 days. An EU prescription for an antimicrobial is valid for five days from issue.
Write the quantity so that it cannot be changed: for controlled drugs in the UK and many other countries the total quantity must be written in words and figures. Prescribe only what is clinically needed, especially for antimicrobials and controlled drugs, and avoid open-ended repeats.
Veterinary prescribing uses Latin abbreviations for frequency and route: SID (semel in die, once daily; this is a veterinary convention, human medicine writes OD or daily), BID (twice daily), TID (three times daily), QID (four times daily), q8h or q12h (every 8 or 12 hours), PRN (as needed), stat (at once), PO (by mouth), SC or SQ (subcutaneous), IM (intramuscular), IV (intravenous), OU, OD and OS (both, right and left eye), AU, AD and AS (both, right and left ear), ac (before food) and pc (after food). Every abbreviation can be misread. OD means right eye to one reader and once daily to another, and a drop meant for one eye may be swallowed. The safest rule is to write the instruction in plain words on the client label, for example give one tablet by mouth every 12 hours with food for 7 days.
Several writing rules prevent tenfold errors. Always put a zero before a decimal point (0.5 mg, never .5 mg), because the decimal point can be missed. Never put a trailing zero after a whole number (5 mg, never 5.0 mg), because 5.0 can be read as 50. Write units in full, not U, which can be read as 0. Write mcg or microgram rather than µg on handwritten scripts, because µ can be read as m. Do not use cc. State the concentration when a drug comes in more than one strength. Where an injectable is prescribed, state mg and mL.
Dispensing is the supply of a medicine against a prescription, with a label and advice. It is a professional act with its own legal duties, whether done by a pharmacist or by a veterinary practice, which in many countries, including the UK, the US and Australia, may dispense for animals under its own care.
The dispenser checks that the prescription is valid and complete, that the prescriber is entitled to prescribe, that the drug, dose and quantity are appropriate for the species and weight, that there are no obvious interactions or contraindications, and that the product chosen matches the prescription. The medicine is picked, counted or measured, and checked again, ideally by a second person. Wherever possible the medicine is supplied in the manufacturer's original pack with its package leaflet, because the leaflet carries safety information. When a pack is split, the client receives the leaflet or an equivalent written copy, and tablets go in a suitable container, child-resistant where possible, never in an envelope that offers no protection from moisture or children.
The label must stay legible and must include, at least: the name and address of the dispensing practice or pharmacy; the client's name and address; the identity of the animal or group; the date; the name, strength and quantity of the medicine; the dose and directions in plain words; the withdrawal period for food-producing animals; warnings such as for animal treatment only and keep out of the reach of children; and, where relevant, storage instructions and the expiry or beyond-use date. Details differ by country. Labels must not obscure the manufacturer's information.
Counselling closes the transaction. Tell the client how and when to give the medicine, what to do about a missed dose, what side effects to watch for, how to store it, how long products from food animals must be withheld, and what to do with leftovers. For high-risk drugs such as NSAIDs in cats or chemotherapy drugs, give written instructions.
Medicines must be stored as the SPC or label directs. Room-temperature storage usually means below 25 °C, protected from direct sunlight. Vaccines, insulin and many biologicals need refrigeration at 2–8 °C and must not freeze; a frozen vaccine may lose potency without any visible change. A practice fridge should be used only for medicines, with a maximum-minimum thermometer or data logger read and recorded daily, and a written plan for power failure.
Once a multi-dose vial is broached its in-use shelf life, stated in the SPC, starts. Mark the date of first opening on the vial and discard it when that period ends, even if liquid remains. Use a new sterile needle for each withdrawal.
Disposal protects people, animals and the environment. Unused and expired medicines are pharmaceutical waste and go to licensed waste contractors, not to drains or household rubbish. Sharps go in rigid sharps containers. Cytotoxic and cytostatic drugs, and items contaminated with them, are hazardous waste handled separately. Controlled drugs must be denatured, rendered irretrievable, before disposal, and in many countries destruction of practice stock must be witnessed by an authorised person and recorded. Medicines returned by clients are never re-dispensed.
Environmental harm is a real concern. Macrocyclic lactone residues in dung harm dung beetles and other invertebrates; diclofenac residues in cattle carcasses caused the collapse of vulture populations in South Asia; and carcasses of animals euthanased with pentobarbital poison scavengers that eat them, so such carcasses must be disposed of securely.
When no authorised veterinary medicine exists for a condition in a particular species, refusing to treat would cause suffering. The cascade is the legal mechanism in the UK and the EU that lets a veterinarian use another medicine, in a fixed order of preference, under his or her own responsibility, for an animal under care, in particular to avoid unacceptable suffering.
In outline the order is: first, a veterinary medicine authorised in the country for another species or for another condition in the same species; if there is none, a human medicine authorised in the country or a veterinary medicine authorised in another country (imported under the regulator's special import arrangements); and if there is none, a medicine prepared extemporaneously by a vet, a pharmacist or an authorised manufacturer to the vet's prescription. In the EU the steps are set out in Articles 112 (non-food species), 113 (food-producing terrestrial species) and 114 (food-producing aquatic species) of Regulation 2019/6. GB's VMD revised its cascade guidance after 2024, including how medicines authorised in Northern Ireland are treated, so check its current version. The vet may move down a step only when no suitable product exists at the step above; cost alone is not a reason.
Extra conditions apply to food-producing animals. Any pharmacologically active substance used must be one that has a maximum residue limit in the relevant list (Table 1 of EU Regulation 37/2010, or the GB equivalent); the vet must set a withdrawal period that is at least the statutory minimum (Chapter 7); and records must be kept. Certain antimicrobials are reserved for human use in the EU and may not be used in animals even under the cascade. The client should give informed consent, ideally in writing, after being told that the product is not authorised for that use and of any known risks. Cascade records in GB must be kept for five years.
In the United States, the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) amended the Federal Food, Drug and Cosmetic Act to permit extra-label drug use (ELDU) by veterinarians, under rules in 21 CFR Part 530. ELDU means use in a manner not on the approved label: a different species, indication, dose, frequency or route, or use contrary to label warnings.
The main conditions are these. ELDU is permitted only by or on the order of a licensed veterinarian within a valid VCPR. It is permitted only for therapeutic purposes, when the animal's health is threatened or suffering or death may result from failure to treat; it is not permitted for production purposes such as growth promotion. It is not permitted in or on animal feed: medicated feed must be used as labelled, and VFD drugs may not be used extra-label. In food animals it must not result in a violative residue; the vet must make a careful diagnosis, establish a substantially extended withdrawal time supported by scientific information, ensure the identity of treated animals is kept, and take steps so that the withdrawal is observed. Approved animal drugs come before human drugs in food animals. ELDU of drugs on the prohibited list in 21 CFR 530.41 is forbidden in food animals (Chapter 9). Extra-label dispensing requires a label with the vet's name and address, the drug's established name, directions including species, dose, frequency, route and duration, cautionary statements and the withdrawal time; records must be kept for two years. The Food Animal Residue Avoidance Databank (FARAD) advises on withdrawal intervals for ELDU.
Elsewhere the rules vary. Canada leaves extra-label use to veterinary discretion with residue-avoidance advice. Australia and New Zealand allow vets to prescribe off-label under state, territory or national control-of-use laws, with restrictions for food-producing species. India's drug law has no formal cascade or extra-label framework comparable to these; Indian veterinarians commonly use human formulations because veterinary ones are unavailable, and should apply the same principles (necessity, informed consent, a conservative withdrawal period, records) while following any national notification.
The withdrawal period (withholding period in Australia and New Zealand, withdrawal time in the US) is the minimum time between the last administration of a medicine and the slaughter of the animal or the collection of milk, eggs or honey for human food, so that residues in the food are below the maximum residue limit. It is a legal requirement, not advice. It is set for each product, species and food type from residue-depletion studies, and may be expressed in days, hours or milkings, or for fish in degree-days.
A withdrawal period is valid only for the labelled use. Anything that slows elimination or adds drug can leave residues above the limit after the label time: a higher dose, more frequent or longer dosing, a different route, a different formulation, injection into a large depot or into fat, use in a different species, renal or hepatic disease, very young animals, mastitis or other inflammation that changes distribution, and drug interactions. Long-acting depot injections leave persistent residues at the injection site, which is why injection sites in food animals should be in the neck rather than the hindquarter.
Products with a zero withdrawal period still need records and correct use, and under EU law a zero must still be written on the prescription. Dry-cow intramammary products carry a minimum dry period and a milk withdrawal after calving; if the cow calves early, milk is withheld until both conditions are met.
Horses are a special case in the UK and EU, where every horse is treated as a food-producing animal unless its passport declares it not intended for human consumption. A horse still in the food chain may receive only substances with an MRL, or substances on the EU list of essential substances for equine species, which carry a six-month withdrawal. Phenylbutazone has no MRL and cannot be used in a food-chain horse.
When a medicine is used off-label in a food-producing animal, the label withdrawal period no longer applies, and the prescriber must set one.
Under the EU cascade, Article 115 of Regulation 2019/6 sets minimums that apply unless the product's SPC already gives a withdrawal for the species concerned. For meat and offal of mammals and birds: the longest withdrawal on the SPC for meat and offal, multiplied by 1.5; 28 days if the product is not authorised for food-producing animals; or 1 day if the product has a zero withdrawal period but is authorised for a different taxonomic family. For milk: the longest milk withdrawal on the SPC for any species, multiplied by 1.5; 7 days if the product is not authorised for lactating animals producing milk for human consumption; or 1 day if the product has a zero withdrawal. For eggs: the longest egg withdrawal multiplied by 1.5, or 10 days if not authorised for laying birds. For fish: the longest fish withdrawal in degree-days multiplied by 1.5; 50 times the longest terrestrial withdrawal in days, expressed as degree-days, if authorised only for terrestrial food animals; 500 degree-days if not authorised for any food species; or 25 degree-days if the highest withdrawal for any species is zero. Great Britain uses the same structure in its cascade guidance, but its egg minimum differs from the EU's, so check the current VMD guidance.
Applying the rule: a product labelled for cattle with a 10-day meat withdrawal used under the cascade in sheep gets at least 1.5 × 10 = 15 days. A product with a 2.5-day milk withdrawal for cattle used in goats gets at least 1.5 × 2.5 = 3.75 days, rounded up to the next whole day (4 days). A product authorised only for dogs used in a pig gets at least 28 days for meat.
A degree-day is one day at 1 °C. At a water temperature of 10 °C, 500 degree-days is 50 days; at 5 °C it is 100 days. Cold water slows fish metabolism and lengthens withdrawal in calendar days.
These minimums are a floor, not a guarantee. In the United States there is no fixed multiplier; the vet must establish a substantially extended withdrawal based on scientific information, typically with FARAD's advice.
A maximum residue limit (MRL) is the highest concentration of a drug residue, usually expressed in micrograms per kilogram of tissue or milk, that is legally permitted in food. The US uses the term tolerance, set in 21 CFR Part 556. International MRLs are set by the Codex Alimentarius Commission on the scientific advice of the Joint FAO/WHO Expert Committee on Food Additives (JECFA); they guide national limits and settle trade disputes under the World Trade Organization's agreement on sanitary and phytosanitary measures.
The derivation starts with the acceptable daily intake (ADI): the amount of a substance, expressed per kilogram of body weight, that a person can eat every day for a lifetime without appreciable risk. The ADI comes from the no-observed-adverse-effect level (NOAEL) in the most sensitive toxicology study divided by a safety factor, usually 100 (10 for differences between species and 10 for variation between people), and larger when the effect is severe or the data are weak. For example, a NOAEL of 5 mg/kg/day divided by 100 gives an ADI of 0.05 mg/kg/day, or 3 mg per day for a 60 kg adult. For antimicrobials, a microbiological ADI based on effects on human gut bacteria is also derived, and the lower of the two is used.
The MRL is then set so that a person eating a standard daily food basket containing residues at the MRL in every item would not exceed the ADI. The EU basket is 300 g muscle, 100 g liver, 50 g kidney, 50 g fat, 1.5 litres of milk, 100 g eggs and 20 g honey. The MRL is set for a marker residue, the parent drug or a metabolite whose concentration tracks total residues, in target tissues where residues persist longest, usually liver or kidney.
For some substances, no ADI can be set because they cause harm at any dose, such as genotoxic carcinogens or drugs that cause idiosyncratic reactions. These receive no MRL and are prohibited in food animals.
In the EU, Regulation (EC) 470/2009 sets the procedure and Commission Regulation (EU) 37/2010 lists the outcome. Table 1 lists allowed substances with their marker residue, species, MRL and target tissue; some appear with the entry no MRL required because they are of low risk. Table 2 lists prohibited substances for which no MRL can be fixed. A substance that appears in neither table may not be given to a food-producing animal in the EU, even under the cascade. India's MRLs and prohibited substances for animal-origin food are in FSSAI's contaminants, toxins and residues regulations, amended in 2024. Codex MRLs are compiled in a document known as CXM 2.
The withdrawal period links the MRL to practice. From a residue-depletion study, regulators find the time at which the upper tolerance limit of residues (in the EU, the 95th percentile with 95% confidence) falls below the MRL in every target tissue, and round up. The MRL is a food standard; the withdrawal period is the instruction that keeps food within it.
Residue surveillance programmes test samples from slaughterhouses, dairies and egg packers for prohibited substances and for residues above MRLs. Violations trigger investigation of the farm and the prescriber. Common causes are failing to observe the withdrawal period, poor treatment records, failure to identify treated animals, off-label use with an inadequate withdrawal, and contaminated feed. On dairy farms, screening tests for beta-lactam and other antibiotic residues are used on bulk milk; a positive load can be rejected. Residues matter because they can cause allergic reactions in sensitised consumers, may select for antimicrobial resistance, can disrupt dairy fermentation, and cost exporters market access.
Some substances are prohibited in food-producing animals because no safe residue level can be set, because their use threatens human medicine through antimicrobial resistance, or because of their effects on the environment. The list differs by country, and a drug banned in one country may be authorised in another, which matters for exports: residues of a substance banned in the importing country lead to rejected consignments.
Chloramphenicol is the classic example. In people it can cause aplastic anaemia that is idiosyncratic and not dose-related, so no ADI can be set; it is banned in food animals in the EU, the US, India and many other countries, and residues in imported shrimp and honey have caused trade alerts. The nitrofurans (such as furazolidone and nitrofurazone) and the nitroimidazoles (metronidazole, dimetridazole, ronidazole) are banned in food animals in the EU and the US because of genotoxic and carcinogenic concerns. EU Table 2 also includes dapsone, colchicine, chlorpromazine, chloroform and Aristolochia species. Hormonal growth promoters, including stilbenes such as diethylstilbestrol, thyrostatics, and beta-agonists used for growth, are banned in EU livestock production; some beta-agonists, such as ractopamine, are approved as feed additives in some countries, such as the United States, but are banned in the EU and China. The EU banned antibiotic growth promoters from 2006 and, under Regulation 2019/6, forbids antimicrobials for growth promotion or to increase yield and restricts prophylaxis to individual animals or a restricted number in exceptional cases.
In the United States, 21 CFR 530.41 lists drugs whose extra-label use in food-producing animals is prohibited: chloramphenicol; clenbuterol; diethylstilbestrol; dimetridazole, ipronidazole and other nitroimidazoles; furazolidone and nitrofurazone, except approved topical uses; sulfonamides in lactating dairy cattle, except approved uses of certain sulfonamides; fluoroquinolones; glycopeptides such as vancomycin; phenylbutazone in female dairy cattle 20 months of age or older; and, with defined exceptions, cephalosporins other than cephapirin in cattle, swine, chickens and turkeys, and adamantane and neuraminidase-inhibitor antivirals in chickens, turkeys and ducks. Where an approved label exists for a listed drug, as with some fluoroquinolones for certain species and indications, on-label use remains lawful; it is the extra-label use that is banned. Clenbuterol is approved for horses but is a prohibited extra-label drug in food animals because of human poisoning from residues in liver and meat.
In India, the Ministry of Health and Family Welfare prohibited colistin and its formulations for food-producing animals, poultry, aqua farming and animal feed supplements in July 2019, to protect colistin as a last-resort human antibiotic. FSSAI's residue regulations name substances that are not permitted in food-producing animals at all, including chloramphenicol, nitrofurans, colistin and malachite green, and set tolerance limits for others; the 2024 amendment applies from April 2025. Veterinary use of diclofenac was banned in 2006 after residues in cattle carcasses were found to be the main cause of the catastrophic decline of Gyps vultures, which develop fatal kidney failure after eating them; in 2023 the ban was extended to ketoprofen and aceclofenac for animal use. Meloxicam has been the vulture-safe alternative most often recommended.
Practitioners must know the list for the country where the animal is and the country its products are sold to. When in doubt, choose a drug with an established MRL and an authorised label for the species.
Controlled drugs are medicines with potential for misuse, dependence or diversion. Their control rests on United Nations treaties, the Single Convention on Narcotic Drugs of 1961 and the Convention on Psychotropic Substances of 1971, which each country implements in its own law. Veterinary practices hold several controlled drugs, including opioids, ketamine, barbiturates and benzodiazepines, and are a recognised target for theft and for misuse by staff.
In the United States, the Controlled Substances Act of 1970, enforced by the Drug Enforcement Administration (DEA), places drugs in Schedules I to V. Schedule I drugs have no accepted medical use. Schedule II drugs, such as morphine, hydromorphone, fentanyl, methadone and single-entity pentobarbital, have the highest abuse potential among usable drugs. Schedule III includes ketamine, tiletamine-zolazepam, buprenorphine, anabolic steroids and pentobarbital euthanasia solutions combined with another active ingredient. Schedule IV includes butorphanol, diazepam, midazolam, phenobarbital and tramadol. Schedule V includes some low-dose codeine preparations and pregabalin. States may schedule additional drugs, such as gabapentin in some states.
In the United Kingdom, the Misuse of Drugs Act 1971 classifies drugs for criminal penalties (Classes A, B and C), and the Misuse of Drugs Regulations 2001 place them in Schedules 1 to 5 for clinical controls. Schedule 2 contains opioids such as morphine, methadone, pethidine and fentanyl; Schedule 3 includes buprenorphine, barbiturates such as pentobarbital and phenobarbital, midazolam and tramadol; Schedule 4 includes most other benzodiazepines, such as diazepam, and anabolic steroids; and Schedule 5 contains low-strength preparations. In India, narcotic drugs and psychotropic substances are controlled under the Narcotic Drugs and Psychotropic Substances Act 1985, alongside the Schedule X controls of the Drugs and Cosmetics Rules; state licences are needed to hold narcotic drugs.
The details are national, but the principles are the same everywhere: control who can order, store securely, record every movement, reconcile stock, and destroy under witness.
In the US a veterinarian must hold a DEA registration for each location where controlled substances are stored or dispensed, plus any state registration. Schedule II drugs are ordered on DEA Form 222 or its electronic equivalent. An initial inventory is taken when registration begins and a full inventory every two years; dispensing and administration records for each controlled substance must be kept for at least two years and be readily retrievable, and some states require longer. Controlled substances must be kept in a securely locked, substantially constructed cabinet. Significant theft or loss must be reported to the DEA in writing within one business day of discovery and then documented on DEA Form 106.
In the UK, Schedule 2 drugs, and some Schedule 3 drugs such as buprenorphine, must be stored in a locked cabinet that meets the Misuse of Drugs (Safe Custody) Regulations 1973, with the key held by an authorised person. Each receipt and supply of a Schedule 2 drug is entered in a controlled-drug register, with a separate page for each drug, form and strength, on the day of the transaction or the next day, and the register is kept for two years from the last entry. Running balances and regular stock checks are good practice and expected by the RCVS. Prescriptions for Schedules 2 and 3 must state the total quantity in words and figures, include the prescriber's registration number and a declaration that the drug is for an animal under the vet's care, and are valid for 28 days. Out-of-date Schedule 2 stock is destroyed in the presence of an authorised witness and recorded.
Practical security includes limiting keys, recording every use against a patient, investigating discrepancies at once, avoiding large stocks, and watching for patterns that suggest diversion, including by clients who seek opioids or benzodiazepines through their animals.
Pharmacovigilance is the detection, assessment, understanding and prevention of adverse effects and other problems with medicines after they reach the market. Pre-authorisation trials involve too few animals, of too few breeds and conditions, to show rare or delayed reactions; these appear only when thousands of animals have been treated. Surveillance after authorisation is how labels gain new warnings, products are withdrawn and doses are revised.
The scope of an adverse event in veterinary pharmacovigilance is wider than in human medicine. Under EU and GB rules, and in VICH guidance, reportable events include: unfavourable and unintended reactions in treated animals, whether or not the product is thought to be the cause, at authorised or off-label doses; lack of expected efficacy, which may signal resistance, for example to anthelmintics or antimicrobials; adverse reactions in people exposed to the product, such as accidental self-injection of oil-adjuvant vaccines, which can cause severe tissue injury, or of tilmicosin, which can be fatal to humans; environmental incidents; violations of MRLs after the stated withdrawal period has been observed, which suggests the period is too short; and suspected transmission of an infectious agent by a product. A serious adverse event is one that results in death, is life-threatening, causes significant disability or incapacity, produces a congenital anomaly, or results in permanent or prolonged signs.
Marketing authorisation holders are legally obliged to collect, record and report adverse events and to run a pharmacovigilance system. In the EU, holders record suspected adverse events in the Union pharmacovigilance database and continuously assess signals. In the United States sponsors must report under FDA rules, with expedited reports for serious unexpected events.
For veterinarians, reporting is a professional duty in most codes, though it is often not a legal obligation. In GB, vets report to the VMD's Suspected Adverse Event Surveillance Scheme, online, or to the company. In the US, vets report drug events to the manufacturer or directly to the FDA on Form FDA 1932a, vaccine events to USDA's Center for Veterinary Biologics, and events involving EPA-registered pesticides, including many topical flea and tick products, to the EPA through the manufacturer. In India, veterinary pharmacovigilance is less developed; report to the manufacturer and the national drug regulator and record the event in the clinical notes.
A useful report includes the reporter's details; the animal's species, breed, age, sex, weight and health status; the product, batch number, dose, route, dates and who gave it; other treatments; the reaction, its timing, severity, treatment and outcome; and whether the drug was stopped and restarted. Do not wait for certainty: a suspicion is enough.
Assessors judge whether the product caused the event by considering timing, known pharmacology, dechallenge and rechallenge, other plausible causes, and post-mortem or laboratory evidence. The EU and GB use the ABON system: A (probable), B (possible), O (unclassifiable or inconclusive) and N (unlikely). Single reports rarely prove causation; patterns across many reports generate signals. Breed-specific sensitivities, such as the ABCB1 (MDR1) gene mutation in collies and related herding breeds that predisposes to macrocyclic lactone neurotoxicity, were recognised partly in this way.
Medicines records protect the animal, the consumer, the client and the veterinarian. They let a practice trace every batch if a recall happens, show that withdrawal periods were set and communicated, reconcile controlled-drug stock, support antimicrobial-use monitoring, and provide the evidence a vet will need if a residue violation, an adverse reaction or a complaint reaches a regulator or court.
Clinical records should show, for every prescribing decision, the examination or assessment that justified it, the diagnosis or working diagnosis, the drug, dose, route, frequency and duration, the quantity supplied, the withdrawal period advised for food animals, the client consent obtained for off-label use, and any adverse event. For cascade or extra-label use, record the reason no authorised product was suitable and the step used.
Supply records under GB's Veterinary Medicines Regulations require, for every receipt and supply of POM-V and POM-VPS medicines, the date, the name of the medicine, the batch number, the quantity, and the name and address of the supplier or recipient; these must be kept for five years, and a detailed audit of stock must be carried out at least once a year. Under EU Regulation 2019/6, retailers and veterinarians keep detailed records of prescription medicines, and keepers of food-producing animals keep records of the medicines they buy and give, for at least five years.
Farmers keep their own medicine records. A typical on-farm record shows the date, animal or group identity, product, batch, quantity given, who gave it, the end date of the withdrawal period and the date the animal or product could enter the food chain.
Retention periods are legal facts that vary by jurisdiction and by type of record, so learn your own and do not assume another country's.
In Great Britain: medicine supply records and cascade records five years; Schedule 2 controlled-drug registers two years after the last entry. In the EU: medicine records of retailers and of food-animal keepers at least five years. In the United States: extra-label use records two years; Veterinary Feed Directive orders two years; controlled-substance records at least two years under federal law, with many states requiring longer; clinical record retention is set by each state, often around three years. In India: the separate Schedule H1 register kept by sellers is retained for three years; clinical record retention for veterinarians is set by state practice and the Veterinary Council's code rather than a single national rule.
Records may be paper or electronic. Electronic records must be secure, backed up, and must show who made each entry and when, with an audit trail of changes; corrections to paper records are made by a single line through the original, initialled and dated, never by erasure.
Good record keeping is also the basis of antimicrobial stewardship. Practices that summarise their antimicrobial use, by class and by species, can benchmark against peers, see where reserved antimicrobials are being used, and act.
A student must be able to write a complete, legible prescription with the correct legal particulars, calculate a dose, an infusion rate and a dilution without a tenfold error, label and dispense a medicine, explain a withdrawal period to a farmer, and say what category a medicine falls in and who may supply it. Exams test these as Day One competences. Practise calculations until they are automatic, learn the safe-writing rules (leading zero, no trailing zero, units in full), and learn the cascade or ELDU conditions in the order they are applied, because licensing papers present them as short clinical scenarios where one condition is missing.
At five years, the vet makes dozens of prescribing decisions a day and is responsible for the practice's medicines. The tasks: choose an authorised product first and document why when stepping down the cascade; set and write a withdrawal period for every food-animal treatment and confirm the farmer understands it; check that each prescription for antimicrobials follows a clinical examination; run the controlled-drug register, reconcile stock weekly and investigate discrepancies at once; record fridge temperatures; report suspected adverse events, including lack of efficacy of anthelmintics; and respond to a residue violation notice with records that show what was prescribed and what was advised.
A senior clinician or practice owner sets the system. Decisions include the practice formulary and antimicrobial policy, who holds controlled-drug keys and how stock checks and destruction are witnessed, how the practice meets record-retention rules in its jurisdiction, and how prescribing for remote or telemedicine consultations is controlled. The senior vet audits antimicrobial use by species and class, benchmarks it, deals with regulators' inspections, advises clients who export animal products on the importing country's banned list, trains staff in dispensing checks and in spotting diversion, and decides when an adverse-event pattern in the practice should be escalated to the regulator and the manufacturer.
At research and policy level the questions are about evidence and law. A pharmacologist with 25 years' experience may design residue-depletion studies and calculate withdrawal periods by the tolerance-limit method, model injection-site residues, contribute to JECFA, Codex or national MRL committees, analyse pharmacovigilance databases for signals, study why withdrawal rules fail on farms, or evaluate whether cascade multipliers are protective for minor species. Policy work includes drafting national rules on off-label use where none exist, as in India, setting reserved-antimicrobial lists, designing antimicrobial-use reporting systems, and assessing the environmental risk of veterinary medicines such as NSAIDs and parasiticides.
This manual teaches principles and well-established examples; it is not a statute book or a formulary. It does not give product doses, product withdrawal periods or national MRL values, which must be read from current labels and lists. GB's cascade guidance was revised after 2024, and its egg minimum and the handling of Northern Ireland-authorised products are not stated here; read the current VMD guidance. The full list of minimum prescription particulars and the maximum validity of a GB POM-V prescription are not tabulated. Indian law is given in general terms: section numbers of the Drugs and Cosmetics Rules other than Rule 97, the exact FSSAI residue tables and the count of regulated antibiotics are left out, because sources conflict. China, Japan, Korea, Brazil and other national medicines laws are not covered. Veterinary compounding rules in the US (FDA guidance on compounding from bulk substances) are described only in outline because they have changed several times. State-level US variations in VCPR, record retention and scheduling are not tabulated. Veterinary pharmacovigilance systems outside the EU, GB and US are not described in detail.
Original practice questions written to the syllabus and pattern of the exams named in each question's examTags. They are not past papers and do not reproduce any board's questions. Drugs in calculation questions are illustrative; confirm any real dose against the product label and your national formulary.
These notes are free to read here, with no account.
What the Laisha app adds:
Free for ten days, then a subscription. We would rather write that here than have you find it later.